New Triple-Threat drug combo aims to tame aggressive prostate cancer
NCT ID NCT04267887
Summary
This study is testing whether a combination of three drugs—apalutamide, abiraterone acetate, and prednisone—can better control advanced prostate cancer that has spread to other parts of the body. The treatment is given to men who have already completed a standard chemotherapy. The goal is to see if this drug combination can more effectively lower PSA levels and control the cancer for a longer time, while also monitoring side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.